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Abstract
Giardiasis, a gastrointestinal disease caused by Giardia duodenalis, is currently treated mainly with nitroimidazoles, primarily
metronidazole (MTZ). Treatment failure rates of up to 20 percent reflect the compelling need for alternative treatment
options. Here, we investigated whether orlistat, a drug approved to treat obesity, represents a potential therapeutic agent
against giardiasis. We compared the growth inhibitory effects of orlistat and MTZ on a long-term in vitro culture adapted G.
duodenalis strain, WB-C6, and on a new isolate, 14-03/F7, from a patient refractory to MTZ treatment using a resazurin assay.
The giardiacidal concentration of the drugs and their combined in vitro efficacy was determined by median-effect analysis.
Morphological changes after treatment were analysed by light and electron microscopy. Orlistat inhibited the in vitro
growth of G. duodenalis at low micromolar concentrations, with isolate 14-03/F7 (IC5024h = 2.8 mM) being more sensitive
than WB-C6 (IC5024h = 6.2 mM). The effect was significantly more potent compared to MTZ (IC5024h = 4.3 mM and 11.0 mM,
respectively) and led to specific undulated morphological alterations on the parasite surface. The giardiacidal concentration
of orlistat was .14 mM for 14-03/F7 and .43 mM for WB-C6, respectively. Importantly, the combination of both drugs
revealed no interaction on their inhibitory effects. We demonstrate that orlistat is a potent inhibitor of G. duodenalis growth
in vitro and kills parasites at concentrations achievable in the gut by approved treatment regimens for obesity. We therefore
propose to investigate orlistat in controlled clinical studies as a new drug in giardiasis.
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Introduction
Giardiasis is caused by the protozoan parasite Giardia duodenalis
(syn. G. intestinalis, G. lamblia) and is one of the most common
parasitic diseases worldwide [1]. It has a significant impact on
public health in both developing and developed countries and was
included in the ‘neglected disease initiative’ of the WHO in 2004
[2]. The life cycle of Giardia spp. is direct and includes flagellated
trophozoites and non-proliferative, infectious cysts that are
transmitted via fecal-oral routes. After ingestion parasites hatch
and undergo transformation into rapidly multiplying trophozoites
that attach to the epithelial layer of the upper small intestine.
G. duodenalis infections remain either asymptomatic or induce
severe and/or chronic (relapsing) disease symptoms, and therefore
treatment is generally indicated [3]. The mechanisms underlying
the pathogenesis of giardiasis are not well understood but
presumably depend on both host and parasite factors [1]. For
example, the G. duodenalis species complex consists of eight main
genotype groups (assemblages) that are morphologically identical
but differ in host specificity. Assemblages A and B show the
broadest host specificity and are the only assemblages that are
pathogenic in humans. Recent data have implied strain-specific
pathogenicity of different genotypes and possibly sub-genotypes in
rodent models [4,5]. In humans, however, association between
specific genotypes and clinical symptoms have been inconclusive
so far [6].
Metronidazole (MTZ) is the first choice for the treatment of
giardiasis, with other nitroimidazoles (e.g. tinidazole) as alterna-
tives. The current model of the mode of action of MTZ proposes
its intracellular reduction to a toxic radical form by various
parasite reductases, including pyruvate:ferredoxin oxidoreductase,
nitroreductase and thioredoxin reductase [7–9]. Alternative
compounds include albendazole, nitazoxanide, paromomycin
and furazolidone. However, most of the therapeutically used
antigiardial drugs, including MTZ cause severe side effects and are
not well tolerated by many patients [3]. Furthermore, clinical
resistance to medication has been observed for all common drugs
in up to 20% of giardiasis cases [3,10,11]. Treatment failure may
be due to both host factors (e.g. low patient compliance due to side
effects) and parasite resistance. The latter has been shown by
several studies demonstrating marked differences in the in vitro
drug susceptibility of isolates from patients [4,12–14]. The
limitations of current antigiardial drugs emphasize the require-
ment of new, efficient and well-tolerated therapeutics [10,11,15].
To this end, reprofiling of compounds that have been approved for
the use in humans is a valid strategy [16–18].
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An efficient lipid metabolism is a sine qua non condition for
rapid proliferation and survival of living organisms. Current data
suggest that G. duodenalis parasites possess only restricted resources
to synthetize and to metabolize lipids [19]. These parasites thus
depend strongly on the exploitation of lipids supplied by the host
environment, rendering therapeutic targeting of enzymes associ-
ated with their lipid metabolism a promising strategy [20].
Tetrahydrolipstatin (orlistat), a derivative of the naturally
occurring lipase inhibitor lipstatin from Streptomyces toxytricini, has
been approved for the treatment of obesity due to its potent
inhibition of pancreatic lipases [21,22]. It is widely used in humans
for this purpose and thus can be considered relatively safe [23–26].
Recently, orlistat has been shown to inhibit the growth of
pathogens, including apicomplexan parasites and trypanosomes,
and that of cancer cells in vitro [18,27–29]. These pharmacological
activities indicate that orlistat has anti-microbial properties and
effects on host cells that may be therapeutically exploitable.
The aim of the present study was to evaluate orlistat for its
in vitro growth inhibitory potential on G. duodenalis alone and in
comparison with MTZ. Our data show a more potent effect of
orlistat on G. duodenalis replication in vitro and suggest that the




The WB-C6 strain of G. duodenalis was derived from the
American Type Culture Collection (ATCC #50803; genotype
AI). Isolate 14-03/F7 was obtained from a human patient
chronically infected and refractory to treatment with MTZ by
in vitro excystation following the protocol of Rice and Schaefer
[30]. Briefly, cysts were enriched from a fresh stool sample by 1 M
sucrose gradient flotation. For in vitro excystation 250 mL (ca.
2.56105 cysts) water-resistant cysts were pre-incubated with
250 mL of an antibiotics mixture (final concentration: erythromy-
cin 136 mM, chloramphenicol 613 mM, amikacin 342 mM, tetra-
cycline 450 mM, rifampicin 243 mM) for 30 min, followed by
addition of 10 mL acidic excystation solution I (5 mL HCl
pH = 2.0; 2.5 mL Hank’s buffered salt solution containing 29 mM
L-cysteine HCl and 67 mM glutathione; 2.5 mL 0.1 M sodium
bicarbonate). After incubating at 37uC for 30 min cysts were
pelleted at 9006g for 5 min, washed once in 10 mL excystation
solution II (0.5% trypsin dissolved in Tyrode solution) and
incubated in 1 mL excystation solution II for an additional
30 min at 37uC. Finally, cysts were sedimented and resuspended
in modified TYI-S-33 culture medium containing an antibiotics
cocktail of lower final concentrations (erythromycin 2.7 mM,
chloramphenicol 12.3 mM, amikacin 6.8 mM, tetracycline
9.0 mM, rifampicin 4.9 mM, fosfomycin 724 mM, penicillin
100 U/mL, streptomycin 172 mM). Serial dilutions of excysting
parasites were seeded into a 96-well plate (200 mL per well) and
incubated under oxygen-deprived conditions (see below) at 37uC.
The isolate 14-03/F7 was derived from one well and was
genotypically characterized at the triosephosphate isomerase locus
by PCR-product sequencing according to a published protocol
[31]. Sequence analysis using defined reference sequences [32]
revealed 100% homology to the reference sequence of AII
(Genbank accession no. U57897).
Growth Conditions
G. duodenalis trophozoites were cultured axenically in 11 mL
screw-cap culture tubes (Nunc) at 37uC in filter-sterilised modified
TYI-S-33 medium containing 10% fetal bovine serum as
previously described [33]. Tubes were filled with at least 10 mL
culture medium to ascertain low-oxygen conditions. Cultures were
split two to three times a week by placing confluent cultures on ice
for 30 min to facilitate detachment of trophozoites that were
further cultured after dilution (1:100 or 1:1000) with fresh culture
medium as described above.
To ascertain optimal oxygen-restricted growth conditions for G.
duodenalis trophozoites that were cultured in cell culture plates or
Petri dishes, the parasites were incubated at 37uC for indicated
times in Aerogen Oxoid jars containing appropriate reaction bags
(Oxoid #AN0025).
Resazurin-assay
Drug susceptibility of G. duodenalis parasites was determined
using a previously described resazurin assay [34] with some
modifications. Briefly, trophozoites were harvested by incubating
the cultures on ice for at least 30 min, followed by centrifugation at
9006g for 10 min at 4uC. Trophozoite pellets were resuspended in
modified TYI-S-33 medium, counted using a Neubauer chamber
and seeded in 200 mL/well of modified TYI-S-33 medium into
black polystyrene 96-well plates with flat clear bottom (Costar
Corning). Trophozoites were incubated at 37uC under oxygen-
restricted growth conditions (see above). To optimize assay
conditions, parasite numbers of 0.56103–16104 per well were
tested. These assays revealed an adequate inoculum size of 56103
trophozoites per well that was used for all subsequent experiments
(see results). After 24 h trophozoites were washed with 200 mL
warm (37uC) phosphate-buffered-saline (PBS), pH 7 and incubat-
ed with 220 mL of resazurin (Sigma R7017, analytical grade) in
PBS per well (final concentration 20 mM) for 4 h at 37uC under
oxygen-deprived conditions. The redox-sensitive dye resazurin
changes from blue/non-fluorescent to the pink/highly-fluorescent
resorufin when reduced by metabolically active trophozoites.
Fluorescence intensity was measured fluorometrically at 595 nm
using a 550 nm excitation wavelength (Tecan Infinite M200 Pro).
To test drug susceptibility trophozoites were incubated with
serial dilutions of the compounds individually or in combination
following the standardised protocol as described above. Stock
solutions of MTZ (Sigma 46461, analytical standard) and of
orlistat (Sigma O4139, purity .98%) were prepared in DMSO
and ethanol, respectively. The final volume of diluent did not
exceed 0.12% (v/v) and had no significant effect on growth of both
G. duodenalis isolates (data not shown). For data analysis, the
fluorescence intensities of treated trophozoites were correlated
with the values of non-treated trophozoites as a control group set
to 100% (percentage of growth). The half maximal inhibitory
concentrations (IC5024h) were calculated from viability plots of
serial drug dilutions using Prism 5 software (GraphPad). The
subscript index indicates the respective assay time used to calculate
the IC50 value (e.g., IC5024h = 24 h assay time).
Calculation of Replication Times
The replication times of the G. duodenalis isolates were derived
from cultures (in triplicates) with an inoculum of 16105 parasites
in 10 mL modified TYI-S-33 medium cultured under oxygen-
restricted growth conditions (see above). After 24, 48, 72, and
96 h, numbers of trophozoites were counted using a Neubauer
counting chamber. For this, the cultures were incubated on ice for
at least 30 min and the parasites collected by centrifugation at 4uC
and 9006g. The doubling time during the log phase was calculated
from growth curves using Prism 5 software.
Inhibition of Giardia duodenalis by Orlistat
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Cell Staining and Light Microscopy
Trophozoites were seeded onto round cover slips placed into a
24-well plate and incubated in the absence or presence of orlistat
(0.1–37.5 mM) in modified TYI-S-33 medium. After 24 h,
Romanowsky staining of the trophozoites was performed accord-
ing to the manufacturer’s protocol (Diff-QuikH, Medion Diagnos-
tics). Cover slips were mounted in Entellan mounting medium
(Merck) and trophozoite morphology was imaged using an Axio
Observer microscope (Carl Zeiss Microscopy).
Electron Microscopy
Cultures of treated and untreated G. duodenalis trophozoites
(WB-C6 strain) were prepared for scanning (SEM) and transmis-
sion (TEM) electron microscopy to reveal the overall morphology
of the trophozoites and ultrastructural elements. Trophozoites
were grown on glass coverslips (16105 trophozoites, for SEM) or
in plastic petri dishes (16107 trophozoites, for TEM) for 24 h at
37uC under oxygen-restricted conditions (see above).
Processing for SEM: Culture medium was removed and
adherent trophozoites were briefly washed with PBS at 37uC
before the pre-warmed fixative, consisting of 4% paraformalde-
hyde, 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2),
was added. Coverslips with adherent trophozoites were post-fixed
with osmium tetroxide (1% in distilled water, for 1 h), dehydrated
in a graded series of ethanol and dried by critical point drying
using carbon dioxide (Emitech K850; Quorum Technologies).
Then, coverslips were mounted onto sample stubs and coated with
a thin layer (about 3 nm) of gold-palladium (Sputter Coating Unit
E5100; Polaron). Finally, samples were examined with a LEO
1530 field-emission scanning electron microscope (Carl Zeiss
Microscopy) at 5 kV using the in-lens secondary electron detector.
Processing for TEM: For fixation, culture medium was removed
and adherent trophozoites were briefly washed with PBS at 37uC,
before the pre-warmed fixative, consisting of 4% paraformalde-
hyde, 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2),
was added. After 2 h incubation at RT trophozoites were stored at
4uC overnight. In parallel, the supernatant collected from the petri
dishes was cooled to 4uC and centrifuged at 9006g for 10 min to
harvest the trophozoites which had detached from the culture dish
surface. The pellet was washed with PBS at 4uC, again centrifuged
at 9006g for 10 min and resuspended with pre-cooled fixative
(composition as above) and fixed overnight at 4uC. The
trophozoites were mixed with fixed trophozoites that had been
scraped from the surface of the corresponding petri dish. The
trophozoites were combined in order to analyse all respective
trophozoites of a given treatment in a single sample which takes
into account that the number of detached cells was too low for an
analysis in some of the treatments. The pooled trophozoites were
embedded in low-melting point agarose and subsequent processing
steps included post fixation in osmium tetroxide (1% in distilled
water), block contrasting with tannic acid (0.1% in 0,05 M Hepes)
and uranyl acetate (2% in distilled water), dehydration and
embedding in epon resin as described by Laue [35]. Ultrathin
sections were prepared using an ultramicrotome (UC7; Leica) and
stained with uranyl acetate (2% in distilled water, 20 min) and lead
citrate (3 min) to increase contrast. The sections were examined
using a Tecnai12 transmission electron microscope (FEI) operated
at 120 kV.
Drug Combination Analysis
The combined effect of MTZ and orlistat on G. duodenalis
growth was determined using the median-drug effect analysis that
involves (i) generation of median-effect plot; (ii) calculation of drug
doses for a given degree of effect; and (iii) calculation of the
combination index (CI) as described by Chou and Talalay [36].
To this end, G. duodenalis trophozoites were incubated with MTZ
(0.33–81 mM) or orlistat (0.33–27 mM) individually and in
combination at different molar ratios of MTZ to orlistat (1:1,
3:1, 1:3 respectively). The CIs for a given degree of inhibition
(fa = fraction affected) were calculated and graphically plotted to
determine whether the underlying combination effect was
synergistic, antagonistic, or not interactive. The interaction of
the combination was defined as showing ‘synergy’ if the CI was
,0.8, ‘no interaction’ effects if the CI was in the range 0.8–1.2,
and ‘antagonism’ if the CI was .1.2 [37,38].
Test of Giardiacidal versus Giardiastatic Effects
Trophozoites were seeded in 24-well plates at a density of
56104 parasites/well (WB-C6) or of 16105 parasites/well (14-03/
F7) and subsequently incubated with various drug concentrations
as indicated for 24 h at 37uC. Then the trophozoites were
detached by incubation on ice for 30 min. All trophozoites
including non-adherent parasites were harvested, pelleted by
centrifugation for 5 min at 9006g and 4uC and finally washed
three times with 5 mL ice-cold PBS to completely remove the
drug. An aliquot was taken to calculate total trophozoite numbers
after drug treatment. The remaining trophozoites were transferred
to 11 mL culture tubes and incubated for 48 h at 37uC in
complete modified TYI-S-33 medium as described above to
determine whether the drugs had effectively killed the trophozoites
or whether trophozoites resumed growth. Total trophozoite
numbers were determined after 24 h and 48 h, respectively. The
detection limit of the counting assay was 2.756103 total
trophozoites.
Statistical Analysis
Statistical analyses were performed using the software program
Prism 5.01 (GraphPad) as stated in the figure legends. Accepted
significance level was p,0.05.
Results
Potent Inhibition of G. duodenalis Replication by Orlistat
To determine the in vitro drug susceptibility of G. duodenalis WB-
C6 trophozoites, we first established a previously described
resazurin to resorufin conversion assay [34]. However, testing
inoculum sizes from 0.56103 to 16104 trophozoites and
incubation times of 24 h–72 h indicated a non-linearity between
parasite numbers and fluorescence intensity of resorufin at 48 h
and 72 h (Fig. 1). Moreover, adopting an inoculum size of 56104
parasites and an incubation time of 72 h in a 96-well plate as
originally described [34] produced in our hands data that were out
of the linear range (data not shown). This is most likely due to
over-growing effects or insufficient surface for attachment of
proliferating parasites, resulting in loss of parasites during
washings. By contrast, satisfactory data sets were achieved with
inoculum concentrations between 0.56103 and 104 parasites/well
and an incubation time of 24 h followed by cultivation with
resazurin for another 4 h. Under these conditions a linear
correlation between parasite numbers and fluorescence intensity
was determined (Fig. 1). For subsequent analysis we therefore used
standardised conditions of 56103 parasites/well and 24 h
incubation time (see methods for details).
Treatment of WB-C6 trophozoites with orlistat revealed a
potent and dose-dependent inhibition of parasite replication
compared to the control (Fig. 2a). The IC5024h of orlistat
(4.361.1 mM) was significantly (p = 0.0039) lower than that of
MTZ (11.061.1 mM). Next, we tested orlistat for its growth
Inhibition of Giardia duodenalis by Orlistat
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inhibitory effects on a newly established G. duodenalis isolate (14-
03/F7) derived from a patient with chronic giardiasis who was
refractory to MTZ treatment. Orlistat (IC5024h of 2.861.2 mM)
was again significantly (p = 0.0079) more effective when compared
with MTZ (IC5024h of 6.261.1 mM) (Fig. 2b). The observed
higher sensitivity of the freshly established isolate to the drugs may
in part be related to slower in vitro growth characteristics [4].
Isolate 14-03/F7 has an apparent generation time of 14 h which is
nearly twice the time of 8 h required by the WB-C6 strain.
Orlistat Treatment Leads to Altered Morphology and
Detachment of G. duodenalis Trophozoites in vitro
Microscopic inspection of trophozoites treated with increasing
concentrations of orlistat revealed a degenerated morphology.
Many parasites detached from the culture plate and were less
motile. To analyse the morphology in more detail, we performed
Romanowsky staining of untreated and orlistat-treated trophozo-
ites. Untreated trophozoites showed the typically pear-shaped
body, pink/purple staining of the cytoplasm and flagella, and two
dark purple nuclei. Upon increasing orlistat concentration, the
flagella of the trophozoites that were still attached to the glass
cover slip became only faintly stained and showed signs of
structural degeneration. The median body was no longer detected
and the parasites lost their clear pear shape of the cell body (Fig. 3).
To further investigate morphological changes G. duodenalis
trophozoites (WB-C6 strain) were analysed by electron microscopy
to reveal ultrastructural changes due to treatment with either
orlistat or MTZ in comparison to respective controls (untreated
and solvent treated trophozoites). Treatment of adhering tropho-
zoites with the drugs induced detachment of a significant number
of trophozoites from the substrate (see above). In SEM analysis,
drug-treated trophozoites that were still adhering appeared slightly
condensed in shape. MTZ-treated trophozoites revealed flagella
with an apparently reduced length (Fig. 4a, b). Orlistat-treated
trophozoites showed a more undulated and blistered dorsal surface
and a large number of flagella displayed terminal blebs which, in
most cases, were single but rarely multiple blebs could be observed
(Fig. 4c–d).
In addition, ultrastructural elements of the trophozoites were
analysed by TEM of ultrathin sections through adherent and
detached trophozoites. Drug-treated trophozoites showed general
structural disintegration, like extracted cytoplasm and the presence
of multilamellar bodies that were not specific for MTZ or orlistat
but rather concentration-dependent (more affected cells with
increasing MTZ or orlistat concentration; not shown). The
cytoskeleton of the cilia and ventral disc was structurally not
affected by either of the treatment, even if trophozoites showed
already significant extraction of the cytoplasm (not shown).
Quantitative changes to the overall shape and size of the median
body could not be reliably analysed but the arrangement of
microtubules within the median body seemed to be unaffected
based on the approximately 20 trophozoite profiles per sample in
which the median body was hit in the section. Differences in the
Figure 1. Establishment of a resazurin-based G. duodenalis
growth assay. Various numbers of trophozoites (WB-C6 strain,
0.56103–104 trophozoites per well) were seeded into 96-well plates.
After 24 h, 48 h or 72 h of culture, the medium was replaced by PBS
and resazurin solution was added. Trophozoites were further incubated
for 4 h and the fluorescence intensity was measured fluorometrically
using an excitation wavelength of 550 nm and an emission wavelength
of 595 nm. Results are presented as fluorescence intensity (RFU) in
relation to the initially inoculated number of trophozoites; Data are
expressed as mean 6 SD of three independent experiments. The
correlation factor (r2) was calculated by linear regression using the
software program Prism 5.01 (GraphPad).
doi:10.1371/journal.pone.0071597.g001
Figure 2. Orlistat inhibits growth of G. duodenalis trophozoites.
Anti-G. duodenalis activity of MTZ (filled circle) and orlistat (blank
squares) was determined in a resazurin assay and results are presented
as relative percentage of growth of the untreated trophozoites as a
control. In addition, the half maximal inhibitory concentrations (IC5024h)
are shown. (A) Growth inhibition curve of the laboratory strain WB-C6;
the IC5024h of orlistat (IC5024h = 4.3 mM; n = 7) was significantly lower
than the IC5024h of MTZ (IC5024h = 11.0 mM; n = 10), p = 0.0034. (B)
Growth inhibition curve of the G. duodenalis patient isolate 14-03/F7;
the IC5024h of orlistat (IC5024h = of 2.8 mM, n = 4) was significantly lower
than the IC50 of MTZ (IC5024h = 6.2 mM; n = 5), p = 0.0079. Data are
expressed as mean 6 SD. The Mann-Whitney-test was used to evaluate
the statistical significance of the differences in IC50 values.
doi:10.1371/journal.pone.0071597.g002
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Romanowsky staining of flagella and median body were therefore
not due to a loss of the microtubular structures but may be related
to other modifications induced by orlistat treatment, e.g.
membrane permeabilization, extraction of cytosolic components
or molecular modifications, which impair the staining.
Orlistat has a Giardiacidal Effect in vitro
To evaluate giardiacidal versus giardiastatic effects of orlistat G.
duodenalis trophozoites were incubated for 24 h in the presence of
56, 106, and 156the IC5024h concentrations (i.e., 21.5, 43 and
64.5 mM orlistat for strain WB-C6 and 14, 28 and 42 mM orlistat
for strain 14-03/F7). MTZ has been shown before to be
giardiacidal [11] and was used as a control at equivalent multiples
of IC5024h doses (55 mM, 110 mM and 165 mM MTZ for WB-C6
and 31, 62 and 93 mM for strain 14-03/F7). As expected from our
previous data, after one day of exposure both drugs caused total
growth inhibition at all concentrations tested. The parasite
numbers corresponded approximately to the inoculated tropho-
zoite number or were even less (Fig. 5). Note that trophozoite
counts included all cells that could be identified as trophozoites,
irrespective of viability.
Further cultivation in growth medium in the absence of the
drugs revealed that orlistat at concentrations higher than 43 mM
(106IC5024h) was sufficient to kill trophozoites of strain WB-C6,
as no further parasite growth was detectable within 48 h (Fig. 5a).
The 24 h-treatment with 56IC5024h orlistat did not kill all
trophozoites, since during the recovery time of 48 h the
trophozoites gained back their replication capability (Fig. 5a). In
contrast, orlistat treatment at a concentration of 56IC5024h
(14 mM) killed all trophozoites of isolate 14-03/F7 indicating strain
or genotype-specific differences in orlistat sensitivity (Fig. 5b). The
treatment of both G. duodenalis strains, WB-C6 and 14-03/F7, with
MTZ at the 56IC5024h concentration was sufficient to kill all
trophozoites (Fig. 5c, 5d).
Independent Inhibition of G. duodenalis Growth by
Orlistat and MTZ
Next, the combined effect of orlistat and MTZ on G. duodenalis
growth was tested. Parasite cultures of WB-C6 and 14-03/F7 were
Figure 3. Orlistat treatment leads to altered morphology of G. duodenalis trophozoites. To analyse trophozoite morphology WB-C6
trophozoites were incubated with increasing orlistat concentrations for 24 h and stained with a Romanowsky stain (DiffQuick). Median body (black
triangle); Flagella (triangle); Nucleus (N). A control, B 3.1 mM, C 6.3 mM and D 25 mM orlistat. Scale bar = 10mm.
doi:10.1371/journal.pone.0071597.g003
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Figure 4. Scanning electron microscopy of orlistat-treated Giardia duodenalis trophozoites (WB-C6 strain) showing altered
morphology. (A) Solvent control (DMSO, 0.1% in medium). (B) MTZ, 11 mM (C) Solvent control (ethanol, 0.12% in medium). (D, E, F) Orlistat, 5 mM.
Controls (A, C) reveal the typical appearance of trophozoites with their pear-shaped cell body and the characteristic arrangement of the eight flagella.
MTZ treated trophozoites (B) possess shorter flagella than the corresponding control trophozoites (A). Orlistat treated trophozoites (D, E, F) appear
shrunken in comparison to corresponding control trophozoites (C) and show blebs on their dorsal surface (arrowheads) as well as at the tip of the
flagella (arrow) (D). (E, F) In some of the trophozoites orlistat mediated effects (blebs at flagella and dorsal cell surface) are more prominent. Scale
bar = 5 mm.
doi:10.1371/journal.pone.0071597.g004
Inhibition of Giardia duodenalis by Orlistat
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treated with the drugs individually over a range of concentrations
(see methods) and in combination at different molar ratios (3:1,
1:1, or 1:3, respectively). The combination index (CI), an
indicative measure of synergistic, antagonistic or summation
effects as defined by Chou and Talaley [36], was determined
and plotted against the normalized effect ( = fraction affected) of
the drug combinations on G. duodenalis growth (Fig. 6). We
considered only CI of fraction affected values .0.5 since lower
values are less relevant for clinical applications [37]. For both G.
duodenalis strains tested the means of the calculated CI values (n
$3) at fraction affected values .0.5 ranged between 0.8 and 1.2,
indicative of no interaction effects of the drug combination orlistat
and MTZ (Fig. 6a, 6b).
Discussion
In the present study we show that the approved anti-obesity
drug orlistat inhibits G. duodenalis growth in vitro. Based on the
calculated molar IC5024h values, orlistat was a significantly more
potent growth inhibitor than MTZ, one of the standard drugs
currently in use to treat giardiasis patients.
Treatment of giardiasis is still a challenge and alternative
therapeutic options are necessary since a substantial proportion of
patients (up to 20%) is refractory to MTZ treatment [3]. Reasons
for treatment failures likely include parasite factors as differences
of in vitro drug sensitivity between laboratory strains and field
isolates and between different human isolates have been reported
[4,7,8,13]. However, the underlying mechanisms of resistance are
not yet fully understood and it is currently not clear if and how
in vitro generated data on drug sensitivity reflect the in vivo situation
in patients. Moreover, comparison of reported drug sensitivity
data from in vitro studies appears critical in view of methodological
differences. For example, using a 24 h assay we determined four to
five times higher IC50 values of MTZ for the G. duodenalis strain
WB-C6 when compared with the values obtained by a similar
technique with a prolonged incubation time of 72 h as previously
reported [34]. Recently, the same group documented a shorter
replication time of genotype AI strains (e.g., WB-C6) versus
isolates of genotype AII, B or EIII [4]. In agreement with this data,
the freshly isolated AII strain 14-03/F7 replicated slower in our
study than the WB-C6 strain. It is currently not known whether
different replication times in vitro are genetically determined and
may therefore be correlated with similar differences in vivo, or
whether a longer replication represents an indicator of stress under
culture conditions. Interestingly, the ratio of the IC5024h values of
MTZ and orlistat were similar for the isolates WB-C6 and 14-03/
F7 (2.6 vs. 2.2, respectively), indicating that the relative efficiency
of the drugs was comparable on both G. duodenalis isolates. Future
Figure 5. Killing of G. duodenalis trophozoites by orlistat. Giardiacidal effects of orlistat or MTZ were determined for drug concentrations
indicated using G. duodenalis strains WB-C6 and 14-03/F7. WB-C6 trophozoites (56104) and 14-03/F7 trophozoites (16105) were treated with orlistat
and MTZ, respectively, for 24 h and, after drug removal, cultured for another 48 h. Trophozoite numbers were determined every 24 h. (A) Orlistat was
used at 56(21.5 mM), 106(43 mM), and 156(64.5 mM) of the IC5024h value for WB-C6. (B) Similarly, MTZ was used at 56(55 mM), 106(110 mM), and
156(165 mM) of the IC5024h concentration for WB-C6. (C) Orlistat was used at 56(14 mM), 106(28 mM), and 156(42 mM) of the IC5024h value for 14-03/
F7. (D) Similarly, MTZ was used at 56(31 mM), 106(62 mM), and 156(93 mM) of the IC5024h concentration for 14-03/F7. Data are expressed as mean 6
SD of parasite numbers determined in triplicate cultures. One of three experiments with similar results is shown (note the gap on the y-intercept).
doi:10.1371/journal.pone.0071597.g005
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studies will be needed to systematically assess the clinical relevance
of in vitro drug sensitivity values.
Our analysis of the combination effects suggests that the mode
of action of MTZ and orlistat is independent. This was also
supported by the specific structural changes as revealed by EM for
the two drugs although the molecular reasons for these changes
remain to be elucidated. With respect to clinical studies, it was
important to analyse possible antagonistic interactions. The
additive inhibitory effect of MTZ and orlistat on G. duodenalis
provides a basis for clinical studies and suggests that a combined
therapeutic application may be beneficial for patients. There is
precedence from individual cases in which combinations of
currently used antigiardial drugs have been successfully applied
for the treatment of patients refractory to single medication [39]. It
should be noted that G. duodenalis is able to rapidly develop
resistance against drugs in vitro [11,40]. Although a similar effect
against orlistat cannot yet be excluded, the use of drugs in
combination may be therapeutically advantageous in that the
development of drug resistance is hampered. However, this will
require comparative clinical studies.
Several criteria motivated us to consider orlistat as a promising
candidate for the treatment of human giardiasis. The mode of
action of orlistat in the treatment of obesity is linked to its covalent
binding to the serine in the active side cleft of the conserved G-X-
S-X-G motif present in pancreatic lipases [21,41]. G. duodenalis has
only a limited set of enzymes for de novo synthesis or remodelling
of lipids and it is thought to be highly dependent on lipid supply
from the host [19,20,42]. Mining of the currently available
genomic data of the three fully sequenced G. duodenalis isolates
(www.giardiadb.org) revealed several putative triglyceride lipases
and phospholipases as potential targets of orlistat (data not shown
and Vargas-Villarreal et al. [43]). These putative G. duodenalis
lipases possess similar G-X-S-X-G motifs. Thus, orlistat may affect
the parasite directly by inhibiting the parasite’s own lipid
metabolizing enzymes and indirectly by limiting the lipid supply
through the inhibition of host enzymes. A conserved motif similar
to the G-X-S-X-G motif in lipases is present in fatty acid synthases
(FAS) that are also potently inhibited by orlistat. Notably,
inhibition of FAS by orlistat potently affects cancer cells and it is
therefore currently considered as a leading compound for the
development of new anti-cancer drugs [28,44]. However, genome
analysis revealed that Giardia spp. likely lack FAS and do not seem
to be capable of de novo synthesis of fatty acids [19]. Although we
cannot exclude off-target effects of orlistat in G. duodenalis we
suggest that the demonstrated giardiacidal effect is due to the
inhibition of parasite lipases. This statement is indirectly supported
by our SEM analysis that revealed for orlistat a specific undulating
and blistering effect on the trophozoite surface suggesting
interference with the metabolism of lipids or other membrane
components. However, the elucidation of the detailed mode of
action of orlistat in G. duodenalis should be addressed in the future,
as this was not the scope of the current study. Furthermore,
findings that orlistat is highly effective against other pathogens
including mycobacteria and protozoan parasites suggest a broad
anti-microbial effect by yet unknown mechanisms
[18,27,29,45,46].
Importantly, orlistat has a very poor intestinal absorption rate
and remains highly effective in the intestinal lumen until it is
excreted with the stool [26,47]. Thus, in the case of giardiasis, this
in situ bioavailability of orlistat should facilitate to sustain a
sufficiently high drug concentration at the site of infection for the
inhibition of parasite lipases. Our in vitro results revealed effective
doses in the micromolar range for both orlistat and MTZ. A
common treatment regimen with MTZ is 36250 mg/d orally for
five to seven days [3]. The drug is well absorbed and distributed,
and in pharmacological studies reached at this dosing 20 mg/mL
plasma peak levels [48] that are equivalent to 116 mM. This
corresponds to ,106the IC5024h that we determined for MTZ in
this study. For orlistat, the recommended dose for obese patients is
120 mg ( = 0.24 mmol) three times a day. Assuming a net amount
of fluid turnover in the human gut of approximately 10 L per day
a rough estimation suggests that the drug may well reach a
concentration of 72.6 mM on average in the intestine, which would
be approximately 17 times higher than the IC5024h value
determined in vitro for G. duodenalis strain WB-C6. Of note, doses
as high as 400 mg of orlistat have been administered in some
clinical studies [26]. Thus, in analogy to MTZ, clinically evaluated
dosage regimens for orlistat may be appropriate to reach
giardiacidal level in vivo.
Figure 6. No interaction effect of MTZ and orlistat in
combination on the growth of G. duodenalis trophozoites.
Trophozoites of G. duodenalis, (A) WB-C6 (n = 4) and (B) 14-03/F7 (n = 3),
were incubated in the presence of various concentrations of MTZ (0.33–
81 mM) or orlistat (0.33–27 mM) alone or in combination. Combination
indices (CIs) of MTZ and orlistat were calculated for given drug ratios
(MTZ:orlistat) of 1:1 (filled circle), 3:1 (open squares), or 1:3 (open
triangle). Results are plotted against the fraction of parasites affected
(normalized growth inhibition). Data are presented as mean 6 SD of
independent experiments (each performed in triplicates). CI values
between 0.8–1.2 (shaded area) indicate no interaction of the drugs
regarding growth inhibition (i.e. drugs act independently).
doi:10.1371/journal.pone.0071597.g006
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Orlistat is generally well tolerated but it should be noted that
prolonged use can cause side effects [23–26,47,49] and impor-
tantly, can interfere with the absorption of concomitantly orally
administered lipophilic drugs [25]. For example, the case of a HIV
patient was recently presented who showed reduced control of
HIV infection under antiretroviral therapy in co-medication with
orlistat presumably due to reduced uptake of Efavirenz, a
lipophilic component of the anti-viral therapy [50]. Although
treatment with orlistat may thus be contraindicated in certain
patients, we still believe that this is not a prohibitive argument
against clinical studies regarding its benefit in MTZ-refractory G.
duodenalis infections.
In conclusion, orlistat not only efficiently killed G. duodenalis
trophozoites in vitro but was also more effective than MTZ. The
demonstrated ‘no interaction’ effect of the drugs in combination
may be beneficial in the treatment of patients suffering from
giardiasis, i.e., reducing the extent of severe side effects caused by
MTZ and the risk of drug resistance, while improving efficacy.
Our data call for controlled clinical studies to evaluate the
usefulness of orlistat in the treatment of giardiasis in humans and/
or animals. This is the first report showing efficacy of orlistat
against a microaerophilic protozoan pathogen. It may also have
activity against other gastrointestinal parasites.
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